Cardiovascular prevention and pitavastatin
Küçük Resim Yok
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Soc Cardiology
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
HMG-CoA reductase inhibitors (statins) represent the most effective class of LDL lowering drugs with an overall positive safety and tolerability profile. They have also consistent benefit in terms of reduced cardiovascular (CV) events in both primary and secondary prevention. Pitavastatin is a new member of the statin class. This review provides a current overview of pravastatin's role in CV risk reduction. In brief pitatastatin has pleitrophic effects as the other statins. It has been shown that it reduces plaque atheroma volume in acute coranary settings. Also the 'real life' evidence gained with pitavastatin in LIVES study, a long-term postmarketing surveillance study in more than 20,000 patients in Japan, denotes an effective CV risk reduction with this new statin.
Açıklama
Anahtar Kelimeler
Kaynak
Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
45
